# A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot

Source: https://onco.cc/trials/nct07543848/  
OnCo record `nct07543848` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab in colorectal cancer, run by Chongqing University Cancer Hospital, not yet recruiting.

## Summary

A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer is a phase 2, interventional study registered as NCT07543848 by Chongqing University Cancer Hospital, with a registry enrolment figure of 20 participants, started 2026-05-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Serplulimab; Oncolytic Virus H101; XELOX Chemotherapy; Short-course Radiotherapy. Conditions listed: Rectal Neoplasms; Rectal Adenocarcinoma. Primary outcome: 1-year Clinical Complete Response Rate. Colorectal eligibility wording from the registry: "Histologically confirmed low rectal adenocarcinoma, with tumor located ≤5 cm from the anal verge". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07543848
- Phase: 2
- Setting: A Prospective, Multicenter, Single-Arm Phase II Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (cT1-3N0M0)
- Sponsor: Chongqing University Cancer Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07543848: https://clinicaltrials.gov/study/NCT07543848

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07543848.json